BO A.I CyberSecurity Scoring
01/05/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Bayer | Ophthalmology in 2026.
No incidents recorded for Bayer | Ophthalmology in 2026.
No incidents recorded for Bayer | Ophthalmology in 2026.
Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines
Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.
Latest updates, reports, and threat intel affecting the global network.
Matthew Alaofin, Senior Advisor at Dell Technologies, USA has disclosed the importance of investment in Autonomous AI and IoT in shaping...
What began as crude phishing emails riddled with spelling mistakes has now evolved into a high-stakes battle against artificial...
A new global business services model needed buy-in across four continents. EY wavespace™ brought execs together to drive inclusive growth.
While hospitality, healthcare sectors boom for freshers, outdated college curriculum fail to impart AI, ML skills; startups fuel jobs for...
Netskope Inc. raised the price of its initial public offering, boosting the potential deal size to $908.2 million from $812.6 million as the...
PITTSBURGH, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Retina Group of Florida (“RGF”) recently announced a cybersecurity incident, which impacted...
Telecommunications giant Optus faces potential civil penalties of up to $20.9 trillion after the Office of the Australian Information...
Here are the worldwide cybersecurity job openings available as of July 29, 2025, including on-site, hybrid, and remote roles.
The Nagaland Police has issued a cybersecurity advisory warning citizens about a malicious mobile application falsely branded as “PM Kisan Yojana.”
ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #133, a normal authenticated user can edit another user's video subtitles because of a lack of authorization. They can upload subtitles, edit their name or delete them. This issue has been patched in version 5.5.3 - #133.
ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #132, any authenticated user who can upload videos can add multiple subtitles from different files and change their title (English, Spanish...). The POST /actions/subtitle_edit.php request used to change their title includes a number parameter which is vulnerable to SQL Injection. A boolean-based blind SQL injection can be used to exfiltrate sensitive data. This issue has been patched in version 5.5.3 - #132.
ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #129, the actions/progress_video.php endpoint is vulnerable to blind SQL injection. Any unauthenticated user can exploit the ids parameter to execute SQL queries and exfiltrate sensitive data. This issue has been patched in version 5.5.3 - #129.
ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #140, ClipBucket's Remote Play feature allows any authenticated user to add a video by importing an external URL as the source. Some shell commands are run with the URL as a parameter. The URL is concatenated directly into shell commands without escaping then executed, so any shell metacharacter in the URL is interpreted. This results in arbitrary command execution. This issue has been patched in version 5.5.3 - #140.
An authenticated format string vulnerability exists in the ONVIF service of Tapo C110 v2 due to improper handling of user-controlled input. Externally controlled data is interpreted as a format string, which can be used to manipulate stack memory, including control flow data such as return addresses. A remote authenticated attacker may redirect execution flow to existing internal functions, triggering an unauthorized factory reset, leading to loss of configuration, deletion of stored credentials and service disruption.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.